- Midatech Pharma PLC MTP has announced a breakthrough in vitro data utilizing Q-Sphera technology and progress across multiple other programs.
- The technology showed potential to formulate proteins into long-acting injectable products.
- Q-Sphera can encapsulate drugs in polymer-based bioresorbable microspheres, which may be injected to form depots in the body that release drugs over predictable, sustained periods from one week to several months.
- Pipeline Update:
- Monoclonal antibody (mAb) formulation: The Company is working on an exemplar mAb and has demonstrated encapsulation of the mAb, preservation of functional integrity, and antigen-binding in vitro.
- MTX214 and MTX216: The Company has manufactured and delivered proof of concept formulations to the collaboration partner. Dosing for in vivo studies will start in the next few weeks.
- MTD211: MTP has developed a long-acting formulation of brexpiprazole.
- In in vivo studies, MTD211 was well tolerated and demonstrated that a single dose could deliver therapeutic blood levels of brexpiprazole over three months.
- Marketed under the brand name Rexulti, brexpiprazole is indicated to treat schizophrenia and adjunctive treatment of major depressive disorder and is available as an immediate release oral tablet.
- MTX110: Formulated panobinostat administered through convection-enhanced delivery, is in clinical development for intractable brain cancers including Diffuse Intrinsic Pontine Glioma (DIPG) and Glioblastoma Multiforme (GBM).
- Phase 2 study in DIPG will start later this year.
- Midatech Pharma's strategy is to develop each program to proof-of-concept before seeking licensing partners for later-stage development and commercialization.
- The Company will be hosting a webinar at 9.00 am EST today.
- Price Action: MTP shares are up 74% at $3.55 during the premarket trading session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
